How Lilly Coordinates Global Manufacturing Changes
This article was originally published in The Gold Sheet
One global manufacturer’s answer to the growing international regulatory thicket that impedes manufacturing changes is a seven-step portfolio management process.
You may also be interested in...
Driven by COVID-19 pandemic challenges, regulatory authorities from multiple regions want to work with sponsors on new joint approaches for expediting manufacturing changes globally and streamlining preapproval and pre-licensing inspections.
Foreign tablets, active pharmaceutical ingredient residues and failed line clearance plagued operations at repackers that received FDA warning letters in FY 2023.
Director of the FDA’s center for drugs slams firm for failing to reach out before suspending operations in the wake of an inspection that raised serious data integrity concerns. Instead, firms should be alerting the agency as soon as they realize there could be shortages.